Overview

We are attempting to harness the immune system to cure child leukemia and to use blood-derived stem cells to cure other life threatening childhood diseases.

Currently, blood and marrow transplantation (BMT) is the only successful form of immune therapy for childhood leukemia. Our research group focuses on harnessing the immune forces unleashed by BMT to improve immune therapy for childhood leukemia. By increasing our understanding of these important immune forces, we hope to also improve the ability to provide safe tissue transplants when needed. Lastly, our group is focused on developing approaches to extend the ability to use blood-derived stem cells to regenerate damaged tissues, correct the immune system, and save children and adolescents from life threatening childhood diseases.

Publications

EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment
Bone Marrow Transplantation
Helene M. Schoemans, Stephanie J. Lee, James L. Ferrara, Daniel Wolff, John E. Levine, Kirk R. Schultz, Bronwen E. Shaw, Mary E. Flowers, Tapani Ruutu, Hildegard Greinix, Ernst Holler, Grzegorz Basak, Rafael F. Duarte, Steven Z. Pavletic
DOI: 10.1038/s41409-018-0204-7
06/2018

Influence of Age on Acute and Chronic GVHD in Children Receiving HLA-Identical Sibling BMT for Acute Leukemia: Implications for Prophylaxis.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
DOI: 10.1016/j.bbmt.2017.11.004
PubMed: 29155316
11/2017

Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
DOI: 10.1016/j.bbmt.2017.06.023
PubMed: 28684372
07/2017

New answers to old conundrums: what antibodies, exosomes and inflammasomes bring to the conversation. Canadian National Transplant Research Program international summit report.
Transplantation
DOI: 10.1097/tp.0000000000001872
PubMed: 28731910
07/2017

Outcome of Hematopoietic Cell Transplantation for DNA-Double Strand Breakage Repair Disorders.
Slack J, Albert MH, Balashov D, Belohradsky BH, Bertaina A, Bleesing J, Booth C, Büchner J, Buckley RH, Ouachée-Chardin M, Deripapa E, Drabko K, Eapen M, Feuchtinger T, Finocchi A, Gaspar HB, Ghosh S, Gillio A, Gonzalez-Granado LI, Grunebaum E
DOI: 10.1016/j.jaci.2017.02.036
PubMed: 28392333
04/2017

Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415].
Couban S, Aljurf M, Lachance S, Walker I, Toze C, Rubinger M, Lipton JH, Lee SJ, Szer J, Doocey R, Lewis ID, Huebsch L, Howson-Jan K, Lalancette M, Almohareb F, Chaudhri N, Ivison S, Broady R, Levings M, Fairclough D
DOI: 10.1016/j.bbmt.2016.09.021
PubMed: 27789277
03/2017

Improved survival after acute graft vs host disease diagnosis in the modern era.
Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M
DOI: 10.3324/haematol.2016.156356
PubMed: 28302712
03/2017

The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.
Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, van den Brink MR, Hansen JA, Parkman R, Miklos DB, Martin PJ, Paczesny S, Vogelsang G, Pavletic S, Ritz J, Schultz KR, Blazar BR
DOI: 10.1016/j.bbmt.2016.09.023
PubMed: 27713092
02/2017

Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia.
Kariminia A, Ivison SM, Leung VM, Sung S, Couto N, Rozmus J, Rolf N, Narendran A, Dunn SE, Reid GS, Schultz KR
DOI: 10.3892/ol.2016.5437
PubMed: 28123588
01/2017

Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.
McMahon KR, Rod Rassekh S, Schultz KR, Pinsk M, Blydt-Hansen T, Mammen C, Tsuyuki RT, Devarajan P, Cuvelier GD, Mitchell LG, Baruchel S, Palijan A, Carleton BC, Ross CJ, Zappitelli M, Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Group
DOI: 10.1177/2054358117690338
PubMed: 28270931
2017

Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research.
Lazaryan A, Wang T, Spellman SR, Wang HL, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, Page K, Bitan M, Reshef R, Drobyski W, Marsh SG
DOI: 10.3324/haematol.2016.143271
PubMed: 27247320
10/2016

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.
Gea-Banacloche J, Komanduri KV, Carpenter P, Paczesny S, Sarantopoulos S, Young JA, El Kassar N, Le RQ, Schultz KR, Griffith LM, Savani BN, Wingard JR
DOI: 10.1016/j.bbmt.2016.10.001
PubMed: 27751936
10/2016

Quantitation of Human Cells that Produce Neutrophils and Platelets in Vivo Obtained from Normal Donors Treated with Granulocyte Colony-Stimulating Factor and/or Plerixafor.
Miller PH, Nakamichi N, Knapp DJ, Rabu G, Schultz KR, Jones DM, Couban S, Eaves CJ
DOI: 10.1016/j.bbmt.2016.07.023
PubMed: 27496214
08/2016

Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.
Couban S, Aljurf M, Lachance S, Walker I, Toze C, Rubinger M, Lipton JH, Lee SJ, Szer R, Doocey R, Lewis ID, Huebsch L, Howson-Jan K, Lalancette M, Almohareb F, Chaudhri N, Ivison S, Broady R, Levings M, Fairclough D
DOI: 10.1016/j.bbmt.2016.04.017
PubMed: 27154847
08/2016

Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation.
Rozmus J, McDonald R, Fung SY, Del Bel KL, Roden J, Senger C, Schultz KR, McKinnon ML, Davis J, Turvey SE
DOI: 10.1016/j.clim.2016.04.011
PubMed: 27109639
07/2016

Exome Sequencing and the Management of Neurometabolic Disorders.
Tarailo-Graovac M, Shyr C, Ross CJ, Horvath GA, Salvarinova R, Ye XC, Zhang LH, Bhavsar AP, Lee JJ, Drögemöller BI, Abdelsayed M, Alfadhel M, Armstrong L, Baumgartner MR, Burda P, Connolly MB, Cameron J, Demos M, Dewan T, Dionne J
DOI: 10.1056/nejmoa1515792
PubMed: 27276562
06/2016

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.
Kariminia A, Holtan SG, Ivison S, Rozmus J, Hebert MJ, Martin PJ, Lee SJ, Wolff D, Subrt P, Abdossamadi S, Sung S, Storek J, Levings M, Aljurf M, Arora M, Cutler C, Gallagher G, Kuruvilla J, Lipton J, Nevill TJ
DOI: 10.1182/blood-2015-09-668251
PubMed: 27020088
06/2016

Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions.
Kumar R, Kimura F, Ahn KW, Hu ZH, Kuwatsuka Y, Klein JP, Pasquini M, Miyamura K, Kato K, Yoshimi A, Inamoto Y, Ichinohe T, Wood WA, Wirk B, Seftel M, Rowlings P, Marks DI, Schultz KR, Gupta V, Dedeken L
DOI: 10.1016/j.bbmt.2016.01.012
PubMed: 26797402
05/2016

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.
Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R, Canadian Blood and Marrow Transplant Group
DOI: 10.1016/s1470-2045(15)00462-3
PubMed: 26723083
02/2016

Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.
Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M
DOI: 10.1182/blood-2015-06-648667
PubMed: 26511135
01/2016

In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children.
Ponce DM, Eapen M, Sparapani R, O'Brien TA, Chan KW, Chen J, Craddock J, Schultz KR, Wagner JE, Perales MA, Barker JN
DOI: 10.1016/j.bbmt.2015.08.022
PubMed: 26327630
12/2015

Functional hyposplenism after hematopoietic stem cell transplantation.
Rozmus J, Mallhi K, Ke J, Schultz KR
DOI: 10.1038/bmt.2015.160
PubMed: 26168071
10/2015

Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.
Ayas M, Eapen M, Le-Rademacher J, Carreras J, Abdel-Azim H, Alter BP, Anderlini P, Battiwalla M, Bierings M, Buchbinder DK, Bonfim C, Camitta BM, Fasth AL, Gale RP, Lee MA, Lund TC, Myers KC, Olsson RF, Page KM, Prestidge TD
DOI: 10.1016/j.bbmt.2015.06.012
PubMed: 26116087
10/2015

Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?
Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll W, Raetz E, Gardner S, Goyal RK, Gastier-Foster J, Borowitz M, Teachey D, Grupp SA
DOI: 10.1038/bmt.2015.103
PubMed: 25961775
09/2015

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.
Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, Hoodin F, Johnston L, Lawitschka A, McDonald GB, Opipari AW, Savani BN, Schultz KR, Smith SR, Syrjala KL, Treister N, Vogelsang GB, Williams KM, Pavletic SZ, Martin PJ
DOI: 10.1016/j.bbmt.2015.03.024
PubMed: 25838185
07/2015

Heterodimer-specific TLR2 stimulation results in divergent functional outcomes in B-cell precursor acute lymphoblastic leukemia.
Rolf N, Kariminia A, Ivison S, Reid GS, Schultz KR
DOI: 10.1002/eji.201444874
PubMed: 25867213
07/2015

Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.
Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pidala J, Olivieri A, Martin PJ, Przepiorka D, Pusic I, Dignan F, Mitchell SA, Lawitschka A, Jacobsohn D, Hall AM, Flowers ME, Schultz KR, Vogelsang G, Pavletic S
DOI: 10.1016/j.bbmt.2015.02.025
PubMed: 25796139
06/2015

Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.
Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F, DeFor TE, Vercellotti GM, Slungaard A, MacMillan ML, Cooley SA, Blazar BR, Panoskaltsis-Mortari A, Weisdorf DJ
DOI: 10.1016/j.bbmt.2015.02.018
PubMed: 25759146
06/2015

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.
Paczesny S, Hakim FT, Pidala J, Cooke KR, Lathrop J, Griffith LM, Hansen J, Jagasia M, Miklos D, Pavletic S, Parkman R, Russek-Cohen E, Flowers ME, Lee S, Martin P, Vogelsang G, Walton M, Schultz KR
DOI: 10.1016/j.bbmt.2015.01.003
PubMed: 25644957
05/2015

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
Pulsipher MA, Carlson C, Langholz B, Wall DA, Schultz KR, Bunin N, Kirsch I, Gastier-Foster JM, Borowitz M, Desmarais C, Williamson D, Kalos M, Grupp SA
DOI: 10.1182/blood-2014-12-615757
PubMed: 25862561
05/2015

NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.
Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, Kreft A, Longerich T, Morton T, Myerson D, Prieto VG, Rosenberg A, Treister N, Washington K, Ziemer M, Pavletic SZ, Lee SJ, Flowers ME, Schultz KR, Jagasia M
DOI: 10.1016/j.bbmt.2014.12.031
PubMed: 25639770
04/2015

Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR
DOI: 10.1016/j.bbmt.2014.10.021
PubMed: 25445023
02/2015

Hematopoietic Cell Transplantation and Cellular Therapeutics in the Treatment of Childhood Malignancies
Pediatric Clinics of North America
Kanwaldeep Mallhi, Lawrence G. Lum, Kirk R. Schultz, Maxim Yankelevich
DOI: 10.1016/j.pcl.2014.10.001
02/2015

TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521).
Yanik GA, Grupp SA, Pulsipher MA, Levine JE, Schultz KR, Wall DA, Langholz B, Dvorak CC, Alangaden K, Goyal RK, White ES, Collura JM, Skeens MA, Eid S, Pierce EM, Cooke KR
DOI: 10.1016/j.bbmt.2014.09.019
PubMed: 25270958
01/2015

Is Any Donor Too Old?
Biology of Blood and Marrow Transplantation
Kirk R. Schultz
DOI: 10.1016/j.bbmt.2014.11.006
01/2015

Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia With Mutations in the WAS gene.
Oshima K, Imai K, Albert MH, Bittner TC, Strauss G, Filipovich AH, Morio T, Kapoor N, Dalal J, Schultz KR, Casper JT, Notarangelo LD, Ochs HD, Nonoyama S
DOI: 10.1007/s10875-014-0105-5
PubMed: 25388447
01/2015

One-unit versus two-unit cord-blood transplantation for hematologic cancers.
Wagner JE, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, Peres E, Verneris MR, Walters M, Horowitz MM, Kurtzberg J, Blood and Marrow Transplant Clinical Trials Network
DOI: 10.1056/nejmoa1405584
PubMed: 25354103
10/2014

Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.
Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Viña M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW
DOI: 10.1182/blood-2014-05-576041
PubMed: 25161269
10/2014

New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.
Pulsipher MA, Wayne AS, Schultz KR
DOI: 10.1038/bmt.2014.114
PubMed: 24933210
10/2014

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.
Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Zheng HW, Davies SM, Gaynon PS, Trigg M, Rutledge R, Jorstad D, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B, Children’s Oncology Group
DOI: 10.1038/leu.2014.30
PubMed: 24441288
07/2014

Combined immunodeficiency associated with homozygous MALT1 mutations.
McKinnon ML, Rozmus J, Fung SY, Hirschfeld AF, Del Bel KL, Thomas L, Marr N, Martin SD, Marwaha AK, Priatel JJ, Tan R, Senger C, Tsang A, Prendiville J, Junker AK, Seear M, Schultz KR, Sly LM, Holt RA, Patel MS
DOI: 10.1016/j.jaci.2013.10.045
PubMed: 24332264
05/2014

Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031.
Schultz KR, Devidas M, Bowman WP, Aledo A, Slayton WB, Sather H, Zheng HW, Davies SM, Gaynon PS, Trigg M, Rutledge R, Jorstad D, Carroll AJ, Heerema N, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B, Children’s Oncology Group
DOI: 10.1038/leu.2014.29
PubMed: 24434862
04/2014

Paroxysmal nocturnal haemoglobinuria phenotype cells and leucocyte subset telomere length in childhood acquired aplastic anaemia.
Tutelman PR, Aubert G, Milner RA, Dalal BI, Schultz KR, Deyell RJ
DOI: 10.1111/bjh.12656
PubMed: 24236830
03/2014

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.
Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL, Raetz E, Gardner S, Gastier-Foster JM, Howrie D, Goyal RK, Douglas JG, Borowitz M, Barnes Y, Teachey DT, Taylor C, Grupp SA
DOI: 10.1182/blood-2013-10-534297
PubMed: 24497539
03/2014

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.
Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T
DOI: 10.1182/blood-2013-10-535716
PubMed: 24435046
03/2014

Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation.
Fernandez-Viña MA, Wang T, Lee SJ, Haagenson M, Aljurf M, Askar M, Battiwalla M, Baxter-Lowe LA, Gajewski J, Jakubowski AA, Marino S, Oudshoorn M, Marsh SG, Petersdorf EW, Schultz K, Turner EV, Waller EK, Woolfrey A, Umejiego J, Spellman SR
DOI: 10.1182/blood-2013-10-532671
PubMed: 24408320
02/2014

Severe combined immunodeficiency (SCID) in Canadian children: a national surveillance study.
Rozmus J, Junker A, Thibodeau ML, Grenier D, Turvey SE, Yacoub W, Embree J, Haddad E, Langley JM, Ramsingh RM, Singh VA, Long R, Schultz KR
DOI: 10.1007/s10875-013-9952-8
PubMed: 24122030
11/2013

Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.
Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Viña M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, Palmer J, Prasad VK, Reddy V, Ringden O, Saber W
DOI: 10.1182/blood-2013-05-501510
PubMed: 23982174
11/2013

STAT3 mutations and persistence of autoimmunity.
Schultz KR
DOI: 10.1182/blood-2013-08-521138
PubMed: 24092924
10/2013

Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study.
Arora M, Pidala J, Cutler CS, Chai X, Kurland B, Jacobsohn DA, Pavletic SZ, Palmer J, Vogelsang G, Jagasia M, Schultz K, Lee SJ
DOI: 10.1038/leu.2012.292
PubMed: 23047477
04/2013

Excess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation: a canadian blood and marrow transplant group trial.
Robitaille N, Lacroix J, Alexandrov L, Clayton L, Cortier M, Schultz KR, Bittencourt H, Duval M
DOI: 10.1016/j.bbmt.2012.12.002
PubMed: 23220014
03/2013

Prediction of area under the cyclosporine concentration versus time curve in children undergoing hematopoietic stem cell transplantation.
Dupuis LL, Seto W, Teuffel O, Gibson P, Schultz KR, Doyle JD, Gassas A, Egeler RM, Sung L, Schechter T
DOI: 10.1016/j.bbmt.2012.10.031
PubMed: 23128321
03/2013

Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease.
Palmer JM, Lee SJ, Chai X, Storer BE, Flowers ME, Schultz KR, Inamoto Y, Cutler C, Pidala J, Arora M, Jacobsohn DA, Carpenter PA, Pavletic SZ, Martin PJ
DOI: 10.1016/j.bbmt.2012.05.005
PubMed: 22691695
11/2012

HLA-matched sibling transplantation for severe aplastic anemia: impact of HLA DR15 antigen status on engraftment, graft-versus-host disease, and overall survival.
Battiwalla M, Wang T, Carreras J, Deeg HJ, Ayas M, Bajwa RP, George B, Gupta V, Pasquini R, Schrezenmeier H, Passweg JR, Schultz KR, Eapen M
DOI: 10.1016/j.bbmt.2012.02.007
PubMed: 22387349
09/2012

Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).
Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, Eapen M, Freed BM, Grimley M, Levine JE, Logan B, Moore T, Panepinto J, Parikh S, Pulsipher MA, Sande J, Schultz KR, Spellman S, Shenoy S
DOI: 10.1016/j.bbmt.2012.01.019
PubMed: 22343376
08/2012

Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.
Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, Winick NJ, Druker BJ, Schultz KR
DOI: 10.1111/j.1365-2141.2012.09039.x
PubMed: 22299775
05/2012

Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens.
Fujii H, Ivison SM, Shimizu H, Kajiwara R, Kariminia A, Yan M, Dutz JP, Schultz KR
DOI: 10.1016/j.bbmt.2011.11.027
PubMed: 22178962
04/2012

Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study.
Gilman AL, Schultz KR, Goldman FD, Sale GE, Krailo MD, Chen Z, Langholz B, Jacobsohn DA, Chan KW, Ryan RE, Kellick M, Neudorf SM, Godder K, Sandler ES, Sahdev I, Grupp SA, Sanders JE, Wall DA
DOI: 10.1016/j.bbmt.2011.05.016
PubMed: 21689773
01/2012

Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031.
Rozmus J, Schultz KR, Wynne K, Kariminia A, Satyanarayana P, Krailo M, Grupp SA, Gilman AL, Goldman FD
DOI: 10.1016/j.bbmt.2011.05.011
PubMed: 21669298
12/2011

Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD.
Chronic GVHD Consortium
DOI: 10.1016/j.bbmt.2011.05.007
PubMed: 21664473
08/2011

Immunosuppressive Therapy Without Hematopoietic Growth Factor Exposure in Pediatric Acquired Aplastic Anemia
Pediatric Hematology and Oncology
Rebecca J. Deyell, Evan B. Shereck, Ruth A. Milner, Kirk R. Schultz
DOI: 10.3109/08880018.2011.568043
06/2011

Biomarkers in chronic graft-versus-host disease
Expert Review of Hematology
Jacob Rozmus, Kirk R Schultz
DOI: 10.1586/ehm.11.27
06/2011

Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children.
Woodard P, Carpenter PA, Davies SM, Gross TG, He W, Zhang MJ, Horn BN, Margolis DA, Perentesis JP, Sanders JE, Schultz KR, Seber A, Woods WG, Eapen M
DOI: 10.1016/j.bbmt.2010.08.016
PubMed: 20813197
05/2011

Controversies in the Treatment of CML in Children and Adolescents: TKIs versus BMT?
Biology of Blood and Marrow Transplantation
Meinolf Suttorp, Isaac Yaniv, Kirk R. Schultz
DOI: 10.1016/j.bbmt.2010.09.003
01/2011

Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.
Schultz KR, Prestidge T, Camitta B
DOI: 10.1586/ehm.10.60
PubMed: 21091149
12/2010

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors.
Shaw PJ, Kan F, Woo Ahn K, Spellman SR, Aljurf M, Ayas M, Burke M, Cairo MS, Chen AR, Davies SM, Frangoul H, Gajewski J, Gale RP, Godder K, Hale GA, Heemskerk MB, Horan J, Kamani N, Kasow KA, Chan KW
DOI: 10.1182/blood-2010-01-261958
PubMed: 20671124
11/2010

Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031.
Cuvelier GD, Kariminia A, Fujii H, Aslanian S, Wall D, Goldman F, Grupp SA, Dunn SE, Krailo M, Shapiro LH, Gilman A, Schultz KR
DOI: 10.1038/bmt.2010.15
PubMed: 20190833
11/2010

Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium.
Pulsipher MA, Horwitz EM, Haight AE, Kadota R, Chen AR, Frangoul H, Cooper LJ, Jacobsohn DA, Goyal RK, Mitchell D, Nieder ML, Yanik G, Cowan MJ, Soni S, Gardner S, Shenoy S, Taylor D, Cairo M, Schultz KR
DOI: 10.1016/j.bbmt.2009.12.536
PubMed: 20079865
09/2010

Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.
Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D
DOI: 10.1200/jco.2010.28.8852
PubMed: 20625136
08/2010

Tumor necrosis factor-alpha gene polymorphisms are associated with severity of acute graft-versus-host disease following matched unrelated donor bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium study.
Goyal RK, Lin Y, Schultz KR, Ferrell RE, Kim Y, Fairfull L, Livote E, Yanik G, Atlas M
DOI: 10.1016/j.bbmt.2010.01.009
PubMed: 20100586
07/2010

Haploidentical transplantation in children.
Schultz KR
DOI: 10.1182/blood-2010-01-263657
PubMed: 20430960
04/2010

Chronic Graft-Versus-Host Disease (GVHD) in Children
Pediatric Clinics of North America
Kristin Baird, Kenneth Cooke, Kirk R. Schultz
DOI: 10.1016/j.pcl.2009.11.003
02/2010

Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
Medyouf H, Gao X, Armstrong F, Gusscott S, Liu Q, Gedman AL, Matherly LH, Schultz KR, Pflumio F, You MJ, Weng AP
DOI: 10.1182/blood-2009-04-214718
PubMed: 20008304
02/2010

Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
Sisler IY, Koehler E, Koyama T, Domm JA, Ryan R, Levine JE, Pulsipher MA, Haut PR, Schultz KR, Taylor DS, Frangoul HA
DOI: 10.1016/j.bbmt.2009.08.014
PubMed: 19896086
12/2009

Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.
Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT, Workshop Participants
DOI: 10.1016/j.jaci.2009.10.022
PubMed: 20004776
12/2009

Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study.
Jacobsohn DA, Gilman AL, Rademaker A, Browning B, Grimley M, Lehmann L, Nemecek ER, Thormann K, Schultz KR, Vogelsang GB
DOI: 10.1182/blood-2009-05-224840
PubMed: 19745067
11/2009

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon PS, Trigg M, Rutledge R, Burden L, Jorstad D, Carroll A, Heerema NA, Winick N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B
DOI: 10.1200/jco.2008.21.2514
PubMed: 19805687
11/2009

Intracranial calcification after cord blood neonatal transplantation for krabbe disease.
Lehman AM, Schultz KR, Poskitt K, Bjornson B, Keyes R, Waters PJ, Clarke LA, Everett R, McConnell D, Stockler S
DOI: 10.1055/s-0029-1243189
PubMed: 20135576
08/2009

The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York.
Duffner PK, Caviness VS, Erbe RW, Patterson MC, Schultz KR, Wenger DA, Whitley C
DOI: 10.1097/gim.0b013e3181a16e04
PubMed: 19346954
06/2009

Optimizing outcomes of hematopoietic stem cell transplantation for severe combined immunodeficiency.
Cuvelier GD, Schultz KR, Davis J, Hirschfeld AF, Junker AK, Tan R, Turvey SE
DOI: 10.1016/j.clim.2009.01.003
PubMed: 19217351
05/2009

44. Outcomes of children transplanted for Krabbe disease
Molecular Genetics and Metabolism
Patricia Duffner, Rajinder Bawa, Martin Champagne, Lawrence Charnas, Morris Kletzl, Daniel Pietryga, Kirk Schultz, Brandon Triplett
DOI: 10.1016/j.ymgme.2008.11.045
02/2009

Controversies of and unique issues in hematopoietic cell transplantation for infant leukemia.
Hunger SP, Loh KM, Baker KS, Schultz KR
DOI: 10.1016/j.bbmt.2008.10.015
PubMed: 19147083
01/2009

Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs.
Griffith LM, Cowan MJ, Kohn DB, Notarangelo LD, Puck JM, Schultz KR, Buckley RH, Eapen M, Kamani NR, O'Reilly RJ, Parkman R, Roifman CM, Sullivan KE, Filipovich AH, Fleisher TA, Shearer WT
DOI: 10.1016/j.jaci.2008.09.045
PubMed: 18992926
12/2008

Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials.
Griffith LM, Pavletic SZ, Lee SJ, Martin PJ, Schultz KR, Vogelsang GB
DOI: 10.1016/j.bbmt.2008.01.005
PubMed: 18342779
04/2008

Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remission.
Barbaric D, Corthals SL, Jastaniah WA, Asalanian S, Shimizu H, Reid GS, Schultz KR
DOI: 10.1111/j.1365-2141.2008.07001.x
PubMed: 18307567
04/2008

Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.
Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A, Krailo M, Chen Z, McMaster R, Bergman A, Goldman F, Grupp SA, Wall DA, Gilman AL, Schultz KR
DOI: 10.1182/blood-2007-08-106286
PubMed: 17925486
03/2008

A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC
DOI: 10.1002/pbc.21132
PubMed: 17262795
02/2008

Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease.
She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z, Reid GS, Wall D, Goldman F, Schultz KR
DOI: 10.1016/j.bbmt.2006.12.441
PubMed: 17382246
04/2007

In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides.
Fujii H, Trudeau JD, Teachey DT, Fish JD, Grupp SA, Schultz KR, Reid GS
DOI: 10.1182/blood-2006-02-002055
PubMed: 17068155
03/2007

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM
DOI: 10.1182/blood-2006-01-024729
PubMed: 17003380
02/2007

Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report.
Satwani P, Sather H, Ozkaynak F, Heerema NA, Schultz KR, Sanders J, Kersey J, Davenport V, Trigg M, Cairo MS
DOI: 10.1016/j.bbmt.2006.09.013
PubMed: 17241927
02/2007

Transplantation for Childhood Acute Lymphoblastic Leukemia
Pediatric Hematopoietic Stem Cell Transplantation
Donna Wall, Kirk Schultz, Gregor Reid
DOI: 10.3109/9780849358807-25
07/2006

Chronic Graft-Versus-Host Disease in Children
Pediatric Hematopoietic Stem Cell Transplantation
David Jacobsohn, Georgia Vogelsang, Kirk Schultz
DOI: 10.3109/9780849358807-5
07/2006

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, Couriel D, Schultz KR, Flowers ME, Filipovich AH, Saliba R, Vogelsang GB, Pavletic SZ, Lee SJ, Design of Clinical Trials Working Group
DOI: 10.1016/j.bbmt.2006.03.004
PubMed: 16635784
05/2006

Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee.
Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR
DOI: 10.1002/pbc.20800
PubMed: 16463346
04/2006

A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.
Marks DI, Forman SJ, Blume KG, Pérez WS, Weisdorf DJ, Keating A, Gale RP, Cairo MS, Copelan EA, Horan JT, Lazarus HM, Litzow MR, McCarthy PL, Schultz KR, Smith DD, Trigg ME, Zhang MJ, Horowitz MM
DOI: 10.1016/j.bbmt.2005.12.029
PubMed: 16545728
04/2006

HLA-DM expression is elevated in ETV6–AML1 translocation-positive pediatric acute lymphoblastic leukemia
Leukemia Research
Wasil A. Jastaniah, Angela J. Alessandri, Gregor S.D. Reid, Kirk R. Schultz
DOI: 10.1016/j.leukres.2005.08.013
04/2006

Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report.
Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S, Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K, Moravec CK, Abramovitz L, Liebermann J, Berger A, Gerber L, Schubert M
DOI: 10.1016/j.bbmt.2006.02.003
PubMed: 16545722
04/2006

Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.
Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H
DOI: 10.1016/j.bbmt.2006.01.008
PubMed: 16503494
03/2006

Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.
Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers ME, Weisdorf D, Couriel D, Lachenbruch PA, Mittleman B, Vogelsang GB, Pavletic SZ
DOI: 10.1016/j.bbmt.2005.11.010
PubMed: 16443511
02/2006

Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.
Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, Moresi JM, Greenson J, Janin A, Martin PJ, McDonald G, Flowers ME, Turner M, Atkinson J, Lefkowitch J, Washington MK, Prieto VG, Kim SK, Argenyi Z, Diwan AH
DOI: 10.1016/j.bbmt.2005.10.023
PubMed: 16399567
01/2006

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M
DOI: 10.1016/j.bbmt.2005.09.004
PubMed: 16338616
12/2005

Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States.
Baker KS, Loberiza FR, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA, Camitta BM, Garcia JJ, Ho WG, Liesveld JL, Maharaj D, Marks DI, Schultz KR, Wiernik P, Zander AR, Horowitz MM, Keating A, Weisdorf DJ
DOI: 10.1200/jco.2005.01.7269
PubMed: 16145067
10/2005

Inhibition of Cathepsin S Alters the T Cell Response to Minor Histocompatibility Antigens09
Journal of Pediatric Hematology/Oncology
Hisaki Fujii, Hiromi Shimizu, Zhijuan Luo, Kirk R Schultz
DOI: 10.1097/01.mph.0000188542.01395.3f
09/2005

Increased TLR9 Responses in B Cells at the Onset of Chronic GVHD36
Journal of Pediatric Hematology/Oncology
Kevin She, Soudabeh Aslanian, Hiromi Shimizu, Andrew L Gilman, Kirk R Schultz
DOI: 10.1097/01.mph.0000188527.40641.1b
09/2005

High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative.
Sutcliffe MJ, Shuster JJ, Sather HN, Camitta BM, Pullen J, Schultz KR, Borowitz MJ, Gaynon PS, Carroll AJ, Heerema NA
DOI: 10.1038/sj.leu.2403673
PubMed: 15789069
05/2005

CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response.
Reid GS, She K, Terrett L, Food MR, Trudeau JD, Schultz KR
DOI: 10.1182/blood-2004-06-2468
PubMed: 15650062
05/2005

The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML).
Hasle H, Baumann I, Bergsträsser E, Fenu S, Fischer A, Kardos G, Kerndrup G, Locatelli F, Rogge T, Schultz KR, Starý J, Trebo M, van den Heuvel-Eibrink MM, Harbott J, Nöllke P, Niemeyer CM, European Working Group on childhood MDS
DOI: 10.1038/sj.leu.2403489
PubMed: 15496981
12/2004

Coronary vessel involvement by chronic graft-versus-host disease presenting as sudden cardiac death.
Prevost D, Taylor G, Sanatani S, Schultz KR
DOI: 10.1038/sj.bmt.1704625
PubMed: 15300232
10/2004

Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors.
Shier LR, Schultz KR, Imren S, Regan J, Issekutz A, Sadek I, Gilman A, Luo Z, Panzarella T, Eaves CJ, Couban S
DOI: 10.1016/j.bbmt.2004.05.009
PubMed: 15319774
09/2004

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH
DOI: 10.1182/blood-2004-01-0338
PubMed: 15039286
07/2004

Expression of the adaptor protein BLNK/SLP-65 in childhood acute lymphoblastic leukemia.
Imai C, Ross ME, Reid G, Coustan-Smith E, Schultz KR, Pui CH, Downing JR, Campana D
DOI: 10.1038/sj.leu.2403349
PubMed: 15029213
05/2004

Canadian multicenter pilot trial of haploidentical donor transplantation.
Walker I, Shehata N, Cantin G, Couture F, Dhédin N, Barty R, Foley R, Sutherland RD, Sigouin C, Schultz KR, Mitchell D, Canadian Blood and Marrow Transplant Group
DOI: 10.1016/j.bcmd.2004.08.006
PubMed: 15528135
2004

Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells.
Reid GS, Terrett L, Alessandri AJ, Grubb S, Stork L, Seibel N, Gaynon P, Schultz KR
DOI: 10.1016/s0145-2126(03)00106-1
PubMed: 12921952
12/2003

Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7.
Kardos G, Baumann I, Passmore SJ, Locatelli F, Hasle H, Schultz KR, Starý J, Schmitt-Graeff A, Fischer A, Harbott J, Chessells JM, Hann I, Fenu S, Rajnoldi AC, Kerndrup G, Van Wering E, Rogge T, Nollke P, Niemeyer CM
DOI: 10.1182/blood-2002-11-3444
PubMed: 12763938
09/2003

Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy.
McCahon E, Sorensen PH, Davis JH, Rogers PC, Schultz KR
DOI: 10.1002/mpo.10272
PubMed: 12652616
05/2003

The impact of Asian descent on the incidence of acquired severe aplastic anaemia in children.
McCahon E, Tang K, Rogers PC, McBride ML, Schultz KR
DOI: 10.1046/j.1365-2141.2003.04236.x
PubMed: 12670349
04/2003

Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission.
Litzow MR, Pérez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA, Gale RP, Giralt SA, Keating A, Lazarus HM, Marks DI, McCarthy PL, Miller CB, Milone G, Prentice HG, Russell JA, Schultz KR, Trigg ME, Weisdorf DJ, Horowitz MM
DOI: 10.1046/j.1365-2141.2002.03973.x
PubMed: 12472596
12/2002

Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD.
Hsiao CC, Su WN, Forooghian F, Bader S, Rempel J, HayGlass KT, Gilman A, Schultz KR
DOI: 10.1038/sj.bmt.1703727
PubMed: 12476284
12/2002

Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line.
Reid GS, Bharya S, Klingemann HG, Schultz KR
DOI: 10.1046/j.1365-2249.2002.01919.x
PubMed: 12165082
08/2002

A population-based study of pediatric anaplastic large cell lymphoma
Cancer
Angela J. Alessandri, Sheila L. Pritchard, Kirk R. Schultz, Bonnie G. Massing
DOI: 10.1002/cncr.10396
03/2002

ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype.
Alessandri AJ, Reid GS, Bader SA, Massing BG, Sorensen PH, Schultz KR
DOI: 10.1046/j.0007-1048.2001.03291.x
PubMed: 11841426
02/2002

Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production.
Schultz KR, Su WN, Hsiao CC, Doho G, Jevon G, Bader S, MacFarlane DE, Gilman AL
DOI: 10.1053/bbmt.2002.v8.abbmt080648
PubMed: 12523576
2002

Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes.
Weisdorf D, Bishop M, Dharan B, Bolwell B, Cahn JY, Cairo M, Giralt S, Klein J, Lazarus H, Litzow M, Marks D, McCarthy P, Miller C, Milone G, Russell J, Schultz KR, Sierra J, Wiernik P, Keating A, Loberiza F
DOI: 10.1053/bbmt.2002.v8.pm12014810
PubMed: 12014810
2002

Absence of t(12;15) associatedETV6-NTRK3 fusion transcripts in pediatric acute leukemias
Medical and Pediatric Oncology
Angela J. Alessandri, Stevan R. Knezevich, Joan A. Mathers, Kirk R. Schultz, Poul H.B. Sorensen
DOI: 10.1002/mpo.1222
2001

Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR, Nevill TJ, Balshaw RF, Toze CL, Corr T, Currie CJ, Strong DK, Keown PA
DOI: 10.1038/sj.bmt.1702545
PubMed: 11019845
09/2000

Treatment of chronic GVHD.
Gilman AL, Schultz KR
DOI: 10.1038/sj.bmt.1702530
PubMed: 10982297
08/2000

Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma
Medical and Pediatric Oncology
Angela J. Alessandri, Karen J. Goddard, Geoffrey K. Blair, Chris J.H. Fryer, Kirk R. Schultz
DOI: 10.1002/1096-911x(200007)35:13.3.co;2-z
07/2000

Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia.
Barrett AJ, Ringdén O, Zhang MJ, Bashey A, Cahn JY, Cairo MS, Gale RP, Gratwohl A, Locatelli F, Martino R, Schultz KR, Tiberghien P
PubMed: 10828011
06/2000

Hydroxychloroquine for the treatment of chronic graft-versus-host disease.
Gilman AL, Chan KW, Mogul A, Morris C, Goldman FD, Boyer M, Cirenza E, Mazumder A, Gehan E, Cahill R, Frankel S, Schultz K
DOI: 10.1016/s1083-8791(00)70058-9
PubMed: 10905770
2000

Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma
Medical and Pediatric Oncology
Angela J. Alessandri, Karen J. Goddard, Geoffrey K. Blair, Chris J.H. Fryer, Kirk R. Schultz
DOI: 10.1002/1096-911x(200007)35:13.0.co;2-7
2000

A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada.
Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR
DOI: 10.1046/j.1365-2141.1999.01645.x
PubMed: 10520007
09/1999

Misleading leads: Bone pain caused by isolated paraspinal extramedullary relapse of childhood acute lymphoblastic leukemia.
Alessandri AJ, Pritchard SL, Massing BG, Sargent MA, Theissen P, Schultz KR
DOI: 10.1002/(sici)1096-911x(199908)33:23.0.co;2-k
PubMed: 10398187
08/1999

The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation.
Schultz KR, Nevill TJ, Toze CL, Corr T, Currie C, Strong DK, Keown PA
DOI: 10.1016/s0041-1345(98)00385-6
PubMed: 9723236
08/1998

Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist?
Schultz KR, Bader S, Nelson D, Wang MD, HayGlass KT
DOI: 10.1097/00007890-199710150-00019
PubMed: 9381529
10/1997

Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia.
Schultz KR, Massing B, Spinelli JJ, Gaynon PS, Wadsworth L
DOI: 10.1002/(sici)1096-911x(199707)29:13.0.co;2-v
PubMed: 9142200
07/1997

Treatment of familial erythrophagocytic lymphohistiocytosis with cyclosporine A
The Journal of Pediatrics
Esteban M. Abella, John Artrip, Kirk Schultz, Yaddanapudi Ravindranath
DOI: 10.1016/s0022-3476(97)70212-9
03/1997

The Lysosomotropic Amines, Chloroquine and Hydroxychloroquine: A Potentially Novel Therapy for Graft-Versus-Host Disease
Leukemia & Lymphoma
Kirk R. Schultz, Andrew L. Gilman
DOI: 10.3109/10428199709039008
01/1997

Immunosuppressive therapy: a potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood?
Lawlor ER, Anderson RA, Davis JH, Fryer CJ, Pritchard SL, Rogers PC, Wu JK, Schultz KR
DOI: 10.1097/00043426-199703000-00004
PubMed: 9149740
1997

Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid.
Schultz KR, Nelson D, Bader S
PubMed: 8879628
09/1996

Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
Schultz KR, Bader S, Paquet J, Li W
PubMed: 7492796
12/1995

Genetic heterogeneity in familial dilated cardiomyopathy.
Schultz KR, Gajarski RJ, Pignatelli R, Goytia V, Roberts R, Bachinski L, Towbin JA
DOI: 10.1006/bmme.1995.1061
PubMed: 8825069
12/1995

Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.
Schultz KR, Paquet J, Bader S, HayGlass KT
PubMed: 7581150
08/1995

Association of gastroesophageal reflux with obstructive lung disease in children after allogeneic bone marrow transplantation.
Schultz KR, Fernandez CV, Israel DM, Magee F, Wensley D, Sargent MA, Abella E, Karanes C
PubMed: 7780159
06/1995

Cyclosporin A therapy of immune-mediated thrombocytopenia in children.
Schultz KR, Strahlendorf C, Warrier I, Ravindranath Y
PubMed: 7858273
03/1995

Obstructive lung disease in children after allogeneic bone marrow transplantation.
Schultz KR, Green GJ, Wensley D, Sargent MA, Magee JF, Spinelli JJ, Pritchard S, Davis JH, Rogers PC, Chan KW
PubMed: 7949192
11/1994

Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
Schultz KR, Ratanatharathorn V, Abella E, Eisenbrey AB, Karanes C, Lum LG, de Planque MM, Uberti JP, Ravindranath Y, Sensenbrenner LL
PubMed: 7920320
06/1994

Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients.
Lum LG, Joshi ID, Galoforo SC, Abella E, Karanes C, Ratanatharathorn V, Schultz KR, Uberti JP, Sensenbrenner LL, Ledbetter JA
PubMed: 8136739
12/1993

An increased relative frequency of retinoblastoma at a rural regional referral hospital in Miraj, Maharashtra, India
Cancer
Kirk R. Schultz, Shashi Ranade, Joseph P. Neglia, Yaddanapudi Ravindranath
DOI: 10.1002/1097-0142(19930701)72:13.0.co;2-a
07/1993

Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes.
Ratanatharathorn V, Karanes C, Uberti J, Lum LG, de Planque MM, Schultz KR, Cronin S, Dan ME, Mohamed A, Hussein M
PubMed: 8471779
04/1993

Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
Ratanatharathorn V, Karanes C, Lum LG, Uberti J, Dan ME, de Planque MM, Schultz KR, Cronin S, Leisz MC, Mohamed A
PubMed: 1543949
01/1992

Effect of interleukin-2 on biodistribution of monoclonal antibody in tumor and normal tissues in mice bearing SL-2 thymoma.
Schultz KR, Badger CC, Dombi GW, Greenberg PD, Bernstein ID
DOI: 10.1093/jnci/84.2.109
PubMed: 1735876
01/1992

Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
Schultz KR, Klarnet JP, Peace DJ, Cheever MA, Badger CC, Bernstein ID, Greenberg PD
PubMed: 2386946
09/1990

The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia.
Schultz KR, Klarnet JP, Gieni RS, HayGlass KT, Greenberg PD
DOI: 10.1126/science.2118273
PubMed: 2118273
08/1990

IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ, Kern DE, Schultz KR, Greenberg PD, Cheever MA
PubMed: 2896213
05/1988

Pathophysiology of Chronic Graft versus Host Disease
Chronic Graft Versus Host Disease
Kirk R. Schultz
DOI: 10.1017/cbo9780511576751.004

Research

Current Projects
My work has evaluated clinically driven issues related to hematopoietic cell transplantation. Clinical investigations have focused on age-related factors affecting graft-versus-host disease (GVHD), graft-failure and graft-versus-leukemia (GVL). Laboratory investigations have used pre-clinical models and the performance of correlative studies in humans to investigate the mechanisms of GVHD and GVL and to develop experimental approaches to modulate these phenomena.

Our laboratory has evaluated the hypothesis that manipulation of MHC class II antigen presentation can alter T cell responses to endogenous antigens. We have investigated the importance of two MHC class II antigen presenting cells in vivo, B cells and dendritic cells, for T cell priming responses to leukemia, and minor histocompatibility antigens (MiHC). We have also investigated whether inhibition of MHC class II antigen presentation by lysosomotropic agents such as chloroquine can inhibit T cell responses to MiHC and development of GVHD. We have translated these pre-clinical observations into clinical studies. We have been one of the first groups to identify chronic GVHD biomarkers in children.

We are also investigating approaches to increasing T cell responses to leukemia by immunization approaches focused on overcoming defects in antigen presentation of endogenous antigens that are either specific to the malignancy or over-expressed in the malignancy. We have focused on the ability of all cells to act as antigen presenting cells and utilizing TLR agonists that affect both leukemic cell immunogenicity and anti-leukemia immune response.

I have been very involved in developing clinical trials focused on improving therapy for GVHD and Acute Lymphoblastic Leukemia. I am a prominent member of clinical co-operative groups including the Children’s Oncology Group (COG), Canadian Blood and Marrow Transplantation Group (CBMTG), Chronic GHVD Consensus Group (NIH sponsored), and C17 (a Canadian pediatric oncology research group). I am currently the group chair of the Pediatric BMT Consortium, a cooperative group that includes over 85 pediatric BMT centers in North America, Australia and New Zealand.

Honours & Awards

Election to Fellowship in the Canadian Academy of Health Sciences (CAHS) – 2014

Canadian National Transplant Research Program, CIHR and Genome BC – 2013

Geoffrey L. Hammond Lectureship Award, CFRI Member Recognition Awards – 2013

Research Group Members

Stephanie Badour, Assistant CRA Manager
Amina Kariminia, Research Assistant TechV
Colleen Jantzen, Research Asst/Tech 3
Ellie Wong, Clinical Research Associate
Marjorie Robbins
Rina Saguin
Masaya Takahashi, Visiting Scientist